MX355457B - Fsh recombinante que incluye alfa, 2-3- y alfa 2,6-sialilacion. - Google Patents

Fsh recombinante que incluye alfa, 2-3- y alfa 2,6-sialilacion.

Info

Publication number
MX355457B
MX355457B MX2017007881A MX2017007881A MX355457B MX 355457 B MX355457 B MX 355457B MX 2017007881 A MX2017007881 A MX 2017007881A MX 2017007881 A MX2017007881 A MX 2017007881A MX 355457 B MX355457 B MX 355457B
Authority
MX
Mexico
Prior art keywords
alpha
signaling
fsh
sialylation
recombinant
Prior art date
Application number
MX2017007881A
Other languages
English (en)
Inventor
Ian Cottingham
Daniel Plaksin
Richard Boyd White
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39717519&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX355457(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of MX355457B publication Critical patent/MX355457B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1081—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C12Y204/99006—N-Acetyllactosaminide alpha-2,3-sialyltransferase (2.4.99.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a una hormona estimuladora de folículo (FSH) recombinante que comprende sialilación a2,3- y sialilación a2, 6-, en donde de 5% a 20% de la sialilación total de la hormona estimuladora de folículo recombinante es sialilación a2,6-.
MX2017007881A 2008-04-16 2009-04-16 Fsh recombinante que incluye alfa, 2-3- y alfa 2,6-sialilacion. MX355457B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4542408P 2008-04-16 2008-04-16
EP08251528 2008-04-25
PCT/GB2009/000978 WO2009127826A1 (en) 2008-04-16 2009-04-16 Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation

Publications (1)

Publication Number Publication Date
MX355457B true MX355457B (es) 2018-04-19

Family

ID=39717519

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2014011348A MX348622B (es) 2008-04-16 2009-04-16 Fsh recombinante que inlcuye alfa 2,3- y alfa 2,6-sialilacion.
MX2010011343A MX2010011343A (es) 2008-04-16 2009-04-16 Fsh recombinante que inlcuye alfa 2,3- y alfa 2,6-sialilacion.
MX2017007881A MX355457B (es) 2008-04-16 2009-04-16 Fsh recombinante que incluye alfa, 2-3- y alfa 2,6-sialilacion.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2014011348A MX348622B (es) 2008-04-16 2009-04-16 Fsh recombinante que inlcuye alfa 2,3- y alfa 2,6-sialilacion.
MX2010011343A MX2010011343A (es) 2008-04-16 2009-04-16 Fsh recombinante que inlcuye alfa 2,3- y alfa 2,6-sialilacion.

Country Status (29)

Country Link
US (7) US8951967B2 (es)
EP (7) EP3098234B1 (es)
JP (7) JP2011519359A (es)
KR (5) KR102108377B1 (es)
CN (3) CN105906703A (es)
AR (1) AR071479A1 (es)
AU (5) AU2009237479B2 (es)
BR (1) BRPI0910461B8 (es)
CA (1) CA2725257A1 (es)
CY (1) CY1115413T1 (es)
DK (6) DK3098234T3 (es)
ES (5) ES2989729T3 (es)
FI (4) FI4015527T3 (es)
FR (3) FR17C1020I2 (es)
HR (5) HRP20241187T1 (es)
HU (9) HUE033830T2 (es)
IL (2) IL208538A (es)
LT (8) LT3045471T (es)
MX (3) MX348622B (es)
NO (4) NO2017025I1 (es)
NZ (1) NZ588381A (es)
PL (6) PL2808340T3 (es)
PT (6) PT3144318T (es)
RU (3) RU2682270C2 (es)
SA (1) SA109300228B1 (es)
SI (6) SI2808340T1 (es)
TW (1) TWI488640B (es)
WO (1) WO2009127826A1 (es)
ZA (1) ZA201007373B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI488640B (zh) 2008-04-16 2015-06-21 菲瑞茵國際中心股份有限公司 藥學製劑
TWI532495B (zh) 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2417982A1 (en) 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
WO2012016576A1 (en) * 2010-08-04 2012-02-09 Glycotope Gmbh Improved recombinant human follicle-stimulating hormone
US9320778B2 (en) 2010-09-29 2016-04-26 Ferring B.V. Method for controlled ovarian stimulation with combined FSH and hCG
CN103154243A (zh) 2010-10-15 2013-06-12 日本化学研究株式会社 糖链的非还原末端为甘露糖残基的糖蛋白的制造方法
CA3163525A1 (en) 2011-03-31 2012-10-04 Ferring Bv. Pharmaceutical preparation
WO2012168680A1 (en) 2011-06-06 2012-12-13 Ferring B.V. Pharmaceutical preparation comprising recombinant fsh
JO3092B1 (ar) * 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
AU2012340501A1 (en) * 2011-12-19 2013-07-11 Grifols, S.A. Compositions, methods, and kits for preparing sialylated recombinant proteins
JP6279466B2 (ja) * 2012-04-27 2018-02-14 Ｊｃｒファーマ株式会社 新規な発現ベクター
EP2824176A1 (en) * 2013-07-11 2015-01-14 Siamed'xpress Methods for producing sialylated therapeutic proteins
JP6652334B2 (ja) * 2014-05-31 2020-02-19 Ｊｃｒファーマ株式会社 ウリジンとｎ−アセチル−ｄ−マンノサミンとを含有する培地
JP2018500934A (ja) * 2014-12-22 2018-01-18 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｃｍｐ依存性シアリダーゼ活性
HUE054300T2 (hu) 2015-04-17 2021-08-30 Ferring Bv FSH-t tartalmazó, meddõség kezelésére szolgáló készítmény
US10906953B2 (en) 2015-06-26 2021-02-02 Ferring B.V. Methods of purification and/or viral inactivation
EP3205719A1 (en) * 2016-02-15 2017-08-16 CEVEC Pharmaceuticals GmbH Cell lines for producing recombinant glycoproteins with di-antennary n-glycans, methods using the same, and recombinant glycoproteins
GB201603280D0 (en) 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation
EP3382014A1 (en) 2017-03-29 2018-10-03 CEVEC Pharmaceuticals GmbH Recombinant glycoproteins with reduced antennary fucosylation
EP3441471A1 (en) 2017-08-08 2019-02-13 CEVEC Pharmaceuticals GmbH Use of constitutively active variants of growth factor receptors as selection makers for the generation of stable producer cell lines
SI3973982T1 (sl) 2017-09-01 2024-10-30 Ferring B. V. Sestavek za nadzorovano stimulacijo jajčnikov
WO2019211153A1 (en) 2018-04-30 2019-11-07 Ferring B.V. Composition for controlled ovarian stimulation
TWI846743B (zh) 2018-10-17 2024-07-01 荷蘭商菲林公司 用於控制性卵巢刺激之組成物及方法
US20220380785A1 (en) * 2019-11-01 2022-12-01 The University Of British Columbia Compositions and methods for sialylated mucin-type o-glycosylation of therapeutic proteins
TW202237173A (zh) 2020-12-09 2022-10-01 荷蘭商菲林公司 用於受控的卵巢刺激之組成物及方法
CN118922201A (zh) 2022-04-01 2024-11-08 辉凌公司 治疗不育症的混合方案
KR20250016113A (ko) 2022-05-26 2025-02-03 훼링 비.브이. 남성 불임 치료를 위한 조성물 및 방법
MA71382A (fr) 2022-07-08 2025-04-30 Ferring B.V. Compositions et procédés d'insémination intra-utérine (iiu)
KR20260041113A (ko) 2023-07-20 2026-03-26 훼링 비.브이. 서방형의 약물-로딩된 마이크로입자

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1206302B (it) 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca Ormone follicolo-stimolante urinario
US5541083A (en) 1989-10-24 1996-07-30 The Regents Of The University Of California Method for producing secretable glycosyltransferases and other golgi processing enzymes
DE69633565T3 (de) 1995-06-15 2013-01-17 Crucell Holland B.V. Verpackungssysteme für humane, menschliche adenoviren, zur verwendung in die gentherapie
JP3559652B2 (ja) * 1996-06-25 2004-09-02 グローリー工業株式会社 売上精算システムの管理装置
TW518235B (en) * 1997-01-15 2003-01-21 Akzo Nobel Nv A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage
AU736993B2 (en) 1997-01-16 2001-08-09 Novo Nordisk A/S Practical in vitro sialylation of recombinant glycoproteins
JPH1111665A (ja) 1997-06-28 1999-01-19 Shibuya Kogyo Co Ltd 無菌エア搬送コンベヤ装置
TWI235158B (en) * 1997-09-01 2005-07-01 Kirin Brewery Human thrombopoietin produced by human established cell lines, processes foe preparing the same, and pharmaceutical composition comprising the same
CA2372714A1 (en) 1999-05-07 2000-11-16 Stephen Franks The use of luteinizing hormone in the induction of pauci-or unifolliculogenesis
JP2002011665A (ja) 2000-06-28 2002-01-15 Sintokogio Ltd ショットブラスト装置モニタシステム
IL140110A0 (en) 2000-12-05 2002-02-10 Applied Research Systems Improvement of homogeneity and secretion of recombinant proteins in mammalian systems
IL161235A0 (en) * 2001-10-22 2004-09-27 Applied Research Systems Fsh composition, its preparation and use
EA008220B1 (ru) 2001-10-29 2007-04-27 Круселл Холланд Б.В. Композиция, включающая эритропоэтинподобные молекулы, и способы ее применения
ATE384785T1 (de) 2001-12-07 2008-02-15 Crucell Holland Bv Herstellung von viren, virusisolaten, und impfstoffen
US20040248784A1 (en) 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
EP1694351A2 (en) * 2003-12-03 2006-08-30 Neose Technologies, Inc. Glycopegylated follicle stimulating hormone
ATE476666T1 (de) 2004-02-04 2010-08-15 Centre Nat Rech Scient Verfahren zur identifizierung von glykoformspezifischen antikörpern
CA2557725C (en) 2004-02-13 2015-06-30 Glycotope Gmbh Highly active glycoproteins-process conditions and an efficient method for their production
TWI488640B (zh) 2008-04-16 2015-06-21 菲瑞茵國際中心股份有限公司 藥學製劑
TWI532495B (zh) 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2417982A1 (en) 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
US8790322B2 (en) 2010-08-03 2014-07-29 King Saud University Stoma coat
WO2012016576A1 (en) * 2010-08-04 2012-02-09 Glycotope Gmbh Improved recombinant human follicle-stimulating hormone
US9320778B2 (en) 2010-09-29 2016-04-26 Ferring B.V. Method for controlled ovarian stimulation with combined FSH and hCG
CA3163525A1 (en) 2011-03-31 2012-10-04 Ferring Bv. Pharmaceutical preparation
WO2012168680A1 (en) 2011-06-06 2012-12-13 Ferring B.V. Pharmaceutical preparation comprising recombinant fsh
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
AR100132A1 (es) 2014-04-18 2016-09-14 Glycotope Gmbh Un método para hiperestimulación ovárica controlada para estimular el desarrollo de múltiples folículos ováricos en un sujeto femenino

Also Published As

Publication number Publication date
EP2268666A1 (en) 2011-01-05
SI3045471T1 (sl) 2017-07-31
KR20110005863A (ko) 2011-01-19
LT2808340T (lt) 2016-11-10
HRP20170958T1 (hr) 2017-09-22
PL3098234T3 (pl) 2025-01-07
JP2011519359A (ja) 2011-07-07
HUS2500029I1 (hu) 2025-07-28
FI3098234T3 (fi) 2024-10-31
EP3045471B1 (en) 2017-03-29
LT3098234T (lt) 2024-09-10
RU2745557C1 (ru) 2021-03-29
US20110105398A1 (en) 2011-05-05
JP6762916B2 (ja) 2020-09-30
CA2725257A1 (en) 2009-10-22
DK4015527T3 (da) 2025-04-14
SI3144318T1 (sl) 2020-12-31
ES2629392T3 (es) 2017-08-09
SI4015527T1 (sl) 2025-05-30
AU2017204258A1 (en) 2017-07-20
US9546204B2 (en) 2017-01-17
FR25C1025I1 (fr) 2025-09-19
EP3098234B1 (en) 2024-07-31
NO2025006I1 (no) 2025-01-16
HUE068565T2 (hu) 2025-01-28
US11952407B2 (en) 2024-04-09
AU2014203277C1 (en) 2017-07-27
MX2010011343A (es) 2011-01-20
PL4015527T3 (pl) 2025-05-26
CY1115413T1 (el) 2017-01-04
NO2017025I1 (no) 2017-06-06
JP2017060476A (ja) 2017-03-30
HUS1700025I1 (hu) 2017-06-28
AU2014203277B2 (en) 2017-04-06
WO2009127826A1 (en) 2009-10-22
PT4015527T (pt) 2025-04-10
NO2025032I1 (no) 2025-07-14
EP3144318A1 (en) 2017-03-22
RU2745557C3 (ru) 2021-12-10
SI2808340T1 (sl) 2016-12-30
SI2268666T1 (sl) 2014-07-31
PT2808340T (pt) 2016-11-21
RU2537268C2 (ru) 2014-12-27
BRPI0910461A8 (pt) 2018-10-16
KR101622944B1 (ko) 2016-05-23
PL3045471T3 (pl) 2017-10-31
EP3045471A1 (en) 2016-07-20
LT3045471T (lt) 2017-07-10
US20150065695A1 (en) 2015-03-05
CN105906703A (zh) 2016-08-31
ES3023526T3 (en) 2025-06-02
PL2268666T3 (pl) 2014-08-29
FR17C1020I1 (es) 2020-04-10
HUE033830T2 (en) 2018-01-29
US20180079794A1 (en) 2018-03-22
HUE030652T2 (en) 2017-05-29
DK3098234T3 (da) 2024-10-21
JP6486310B2 (ja) 2019-03-20
US20240327487A1 (en) 2024-10-03
PT3045471T (pt) 2017-06-14
KR102108377B1 (ko) 2020-05-08
BRPI0910461A2 (pt) 2018-03-27
HUS2500008I1 (hu) 2025-02-28
KR20180095140A (ko) 2018-08-24
PT3144318T (pt) 2020-11-04
US9771407B2 (en) 2017-09-26
AU2017225020A1 (en) 2017-09-28
EP4015527B1 (en) 2025-01-22
FIC20250025I1 (fi) 2025-07-11
EP3098234A1 (en) 2016-11-30
JP7316905B2 (ja) 2023-07-28
AU2017225020B2 (en) 2019-11-14
LTPA2017018I1 (lt) 2017-06-26
ZA201007373B (en) 2011-06-29
FR17C1020I2 (fr) 2020-04-10
FIC20250003I1 (fi) 2025-01-15
US20210332099A1 (en) 2021-10-28
US10995128B2 (en) 2021-05-04
RU2014141994A (ru) 2016-05-10
JP2024038000A (ja) 2024-03-19
SI3098234T1 (sl) 2024-10-30
US8951967B2 (en) 2015-02-10
PT3098234T (pt) 2024-10-21
TW200948378A (en) 2009-12-01
RU2010141908A (ru) 2012-05-27
IL208538A (en) 2014-03-31
KR20160056960A (ko) 2016-05-20
AR071479A1 (es) 2010-06-23
HRP20241187T1 (hr) 2024-12-06
MX348622B (es) 2017-06-22
HUS1700036I1 (hu) 2017-10-30
JP2015120696A (ja) 2015-07-02
DK2268666T3 (da) 2014-05-12
TWI488640B (zh) 2015-06-21
BRPI0910461B8 (pt) 2021-05-25
CN102066414A (zh) 2011-05-18
US12516094B2 (en) 2026-01-06
FR25C1003I1 (fr) 2025-02-28
RU2014141994A3 (es) 2018-05-28
ES2468318T3 (es) 2014-06-16
AU2009237479A1 (en) 2009-10-22
US20160347811A1 (en) 2016-12-01
AU2017204259B2 (en) 2017-08-17
IL230571A (en) 2015-11-30
BRPI0910461B1 (pt) 2021-02-23
JP2020040956A (ja) 2020-03-19
HUE071059T2 (hu) 2025-07-28
KR20190092608A (ko) 2019-08-07
ES2989729T3 (es) 2024-11-27
DK2808340T3 (en) 2016-12-05
AU2017204259A1 (en) 2017-07-20
NO2017050I1 (no) 2017-09-28
LT4015527T (lt) 2025-04-10
EP2808340A1 (en) 2014-12-03
IL208538A0 (en) 2010-12-30
PL2808340T3 (pl) 2017-02-28
PL3144318T3 (pl) 2021-02-08
HRP20161520T1 (hr) 2016-12-30
RU2682270C2 (ru) 2019-03-18
HUE030652T4 (en) 2017-09-28
HRP20250313T1 (hr) 2025-05-09
HK1146284A1 (en) 2011-05-20
LTPA2017029I1 (lt) 2017-10-10
EP2268666B1 (en) 2014-03-12
LTPA2025505I1 (es) 2025-02-10
AU2017204258B2 (en) 2017-08-17
HK1199039A1 (en) 2015-06-19
KR20170110741A (ko) 2017-10-11
JP2018021037A (ja) 2018-02-08
DK3144318T3 (da) 2020-12-07
JP2022031652A (ja) 2022-02-22
US20260217782A1 (en) 2026-07-30
AU2009237479B2 (en) 2014-05-15
CN105906702A (zh) 2016-08-31
ES2610277T3 (es) 2017-04-26
HRP20140535T1 (hr) 2014-07-18
AU2014203277A1 (en) 2014-07-24
SA109300228B1 (ar) 2014-04-08
EP3144318B1 (en) 2020-09-23
NZ588381A (en) 2012-05-25
PT2268666E (pt) 2014-06-25
HUS1700024I1 (hu) 2017-06-28
DK3045471T3 (en) 2017-06-26
EP2808340B1 (en) 2016-08-17
FI4015527T3 (fi) 2025-04-29
LTPA2025525I1 (es) 2025-07-25
EP4015527A1 (en) 2022-06-22
EP2722339A1 (en) 2014-04-23

Similar Documents

Publication Publication Date Title
MX348622B (es) Fsh recombinante que inlcuye alfa 2,3- y alfa 2,6-sialilacion.
AR125991A2 (es) Preparación farmacéutica
CR20130144A (es) Adhesivos de soja y compuestos hechos a partir de los adhesivos
CO6531500A2 (es) Composiciones y metodos para el tratamiento de la xerostomia
BR112012009135A2 (pt) composição polímera termoplástica
BR112013001063A2 (pt) composição para cuidados pessoais compreendendo um composto com ramificações próximas á extremidade
GT201200046A (es) Conjugados de dímeros de pirrolo[1,4] benzodiazepina como agentes anticancerosos
UY33625A (es) Uso de ingredientes activos para controlar nematodos en cultivos resistentes a nematodos
BRPI0901553A2 (pt) máscara facial
DOP2012000175A (es) Analogo peptidico de oxintomodulina
BR112015019817A2 (pt) interface de vedação para um compartimento de telecomunicações
CR20120264A (es) Compuestos
BR112013022563A2 (pt) fecho para uma seringa e processo de produção do mesmo
BR112013023829A2 (pt) âncora de sutura plana
BR112012011467A2 (pt) forma glicosilada de análogo ao glp-1 antigênico.
BR112015027432A2 (pt) 3-(4-isobutil-2-metilfenil)propanal como ingrediente de perfume
MX336715B (es) Purificacion de iduronato-2-sulfatasa.
GB0910082D0 (en) Two-part valve
BR112012017167A2 (pt) processo para a produção de óxido de olefina
EP2636718A3 (en) White light emitting device
AR043783A1 (es) Difenilazetidinona con propiedades fisiologicas, medicamentos que comprenden este compuesto y su uso
BRPI0917656A2 (pt) Fatores viii e ix humanos produzidos de forma recombinante
DE502007005946D1 (de) Auto-adhäsiver klebstoff
CR20130181A (es) UNA COMPOSICIÓN QUE COMPRENDE 2-metilpropanotioato de S-[2-([[1-(2-etilbutil)ciclohexil]-carbonil]amino)fenilo] Y CROSCARMELOSA SODICA
BR112015013406A2 (pt) composição adesiva sensível à pressão